


VTSEGAGLQK-¹³C₆,¹⁵N₂

Cat. No.:	HY-P5201S
Molecular Formula:	C ₄₆ ¹³ C ₆ H ₉₁ N ₁₃ ¹⁵ N ₂ O ₁₉
Molecular Weight:	1238.31
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	VTSEGAGLQK- ¹³ C ₆ , ¹⁵ N ₂ is the ¹³ C and ¹⁵ N labeled VTSEGAGLQK. VTSEGAGLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect ^{[1][2]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-217.
- [2]. Bronsema KJ, et al. Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human α -glucosidase in human plasma using protein G extraction and LC-MS/MS. *Anal Chem*. 2015 Apr 21;87(8):4394-401.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA